Re: Exten Industries

Up 14% today on 3,000,000 shares..Do your DD and get in while the getting is good. 

[EMAIL PROTECTED] (ccc343) wrote in message news:<[EMAIL PROTECTED]>...
> Repost of message from Ragingbull.com EXTI message board
> Written by alandail
> 
> Exten Industries (EXTI) overview 
> 
> Thanks to better understanding on my part and feedback I've received,
> I've completely rewritten this. Any additional feedback to make this
> clearer would be appreciated.
> 
> The Exten Industries business is built around a revolutionary liver
> cell lines they have developed and patented. These offer many
> significant advantages, including they are:
> 
> 1 - human (as opposed to porcine) 
> 2 - nontumorigenic (non-cancerous, as opposed to other's cancerous
> human cell lines)
> 3 - immortilized (The ability of a genetically engineered cell line to
> reproduce indefinitely)
> 4 - fully-functional (as discovered by Pfizer & now, Roche, & as
> opposed to others, which aren't)
> 5 - readily available (as opposed to porcine, rat or human liver
> "slices")
> 6 - cost-effective (as opposed to porcine, rat or human liver
> "slices")
> 
> These cell lines have been validated by both Pfizer and
> Hoffman-LaRoche - Pfizer signed a 15 year license after their
> evaluation, it remains to be seen what Hoffman-LaRoche will do as they
> just presented on wednesday. These cell lines are enabling EXTI to
> enter, and possibly dominate 4 major markets - I'm listing these in
> the order I think they will be able to enter the respective markets.
> 
> 1 - the $3.7 billion Hepatocyte Test Kit market through their
> MultiCell subsidiary. Through their world wide marketing and
> distribution agreement with XenoTech has these test kits on the market
> today, with their product launch at the ISSX Meeting beginning Oct 12,
> 2003. Many expect this cell line to become the gold standard for this
> market. Their contract with XenoTech has already resulted in a 1.5
> million payment, guarantees a minimum of $18 million in royalties over
> 7 years. Both numbers are enough to make EXTI profitable and it is
> expected the actual numbers will far exceed these guaranteed amounts.
> 
> 2 - the $43 billion Therapeutic Protein Production market through
> their MultiCell subsidiary. Being fully functional liver cells, they
> can generate therapeutic proteins with high yield and low cost vs.
> current methods.
> 
> 3 - the $2 billion bioartificial liver market through their Xenogenics
> subsidiary. Think of it as dialysis for the liver. Again, these fully
> functional immortalized liver cell lines give EXTI a major advantage
> in this market.
> 
> 4 - the $78 billion Liver Stem Cell Transplantation market. The holy
> grail of liver research - be able to regenerate damaged liver tissue.
> 
> For more information, see 
> 
> http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=5678 
> http://exti.info/ 
> http://exten.com/ 
> http://finance.yahoo.com/q/is?s=EXTI.OB